AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00002824
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00136825
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01724424
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg oral single dose
Trial: NCT01724424
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 30 mg oral single dose
Trial: NCT01724424
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50mg oral single dose
Trial: NCT01724424
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100mg oral single dose
Trial: NCT04035096
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. Start with IVC (intravenous ascorbic acid) 25 g biweekly, 50 g biweekly, and 75 g biweekly. If the target blood level is below 350mg/dl, the dose will titrate up to 100 g/dose or maximal dose of 1.5g/kg/dose to achieve the target level.~2. The final dose will be kept for 12 weeks.~3. Maintenance dose: 75-100g every 2 week will be maintained for additional 12 weeks
Trial: NCT00206284
Drug: AZD0865
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00432744
Drug: CoenzymeQ10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoenzymeQ10 will be given in 10 mg/kg daily up to 400 mg. Then a draw of CoQ10 troughs every three months will be performed.
Trial: NCT00432744
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given in 10 mg/kg daily up to 400 mg. Then a draw of placebo troughs every three months will be performed. This treatment group will be treated as the active group.
Trial: NCT03844113
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participant will be given a daily oral dose 2 g of methycellulose powder for 6 months
Trial: NCT00005013
Drug: Hypericum perforatum (St. John's wort)
RxNorm normalized name: HYPERICUM PERFORATUM (ST. JOHN'S WORT)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00468845
Drug: matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matched placebo
Trial: NCT03216486
Drug: BPS804
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV administration of BPS804 in 5% Dextrose solution
Trial: NCT01228994
Drug: placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo pill
Trial: NCT03553498
Drug: IV acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acetaminophen given intravenously
Trial: NCT03553498
Drug: IV placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: given intravenously
Trial: NCT04272008
Drug: Segesterone Acetate and Ethinyl Estradiol
RxNorm normalized name: ETHINYL ESTRADIOL/SEGESTERONE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annovera taken alone
Trial: NCT01887119
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04867941
Drug: ACP-196
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All study participants will receive a single oral dose of 50 mg ACP-196 (2 x 25 mg capsules) on Day 1 of the study.
Trial: NCT03596073
Drug: Topical Calcipotriene Ointment
RxNorm normalized name: calcipotriene Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriene is a form of vitamin D. It works by slowing down the growth of skin cells.
Trial: NCT01708447
Drug: L.M.X.4.® cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A lidocaine topical anesthetic cream
Trial: NCT02333149
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo frequency and volume are identical to the experimental arm
Trial: NCT00030771
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (Taxotere®) 85 mg/m2 1 hour iv infusion d1 Cisplatin 100 mg/m2 1 hour iv infusion d1 Schedule: 3 cycles repeated every 21 days
Trial: NCT01442792
Drug: UFH
RxNorm normalized name: Ibrufhalal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unfractionated Heparin: 70-100 IU/Kg bolus and adjusted upon activated coagulation time (ACT) 250 300 seconds
Trial: NCT02581462
Drug: FLOT alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-operative therapy:~* Docetaxel 50 mg/m², d1, d15, d29, d43~* Oxaliplatin 85 mg/m², d1, d15, d29, d43~* Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~* 5-FU 2600 mg/m², d1, d15, d29, d43~Surgery is recommended to be scheduled 4 weeks after d43.~Post-operative therapy (start 6 to 8 weeks after surgery):~* Docetaxel 50 mg/m², d1, d15, d29, d43~* Oxaliplatin 85 mg/m², d1, d15, d29, d43~* Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~* 5-FU 2600 mg/m², d1, d15, d29, d43
Trial: NCT00906451
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin
Trial: NCT03132519
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To maintain remifentanil Ce at 1.0 (control) vs. 2.0 vs. 2.5 ng/ml by a TCI system during anesthesia emergence until tracheal extubation
Trial: NCT00549185
Drug: SAR3419
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT04102553
Drug: F-18-PSMA-1007
RxNorm normalized name: PSMA-1007 (18F)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.
Trial: NCT04102553
Drug: F-18-Fluorocholine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.
Trial: NCT00098722
Drug: optimized background therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[OBT (3-6 drugs based on treatment history and resistance testing)\]
Trial: NCT00552630
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo with same characteristics as drug
Trial: NCT00934947
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar pill
Trial: NCT03384823
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to match EDP-938
Trial: NCT02898961
Drug: 30 mg/kg amikacin or 8 mg/kg gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In order to improve the achievement of target peak concentrations, either 30 mg/kg amikacin or 8 mg/kg gentamicin was prescribed in ICU patients with severe sepsis.~In combination with broad-spectrum antibiotics, according to the suspected pathogens and local clinical practice, 30 mg/kg amikacin or 8 mg/kg gentamicin was given (30 min intravenous infusion; the dosage ampoule was systematically emptied with a 5 ml flush). The peak serum concentration sampling occurred 30 minutes after the end of the infusion.
Trial: NCT00736775
Drug: anti-Abeta
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous single and multiple doses
Trial: NCT00736775
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous single and multiple doses
Trial: NCT03518268
Drug: Vivomixx
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention consists of 2 sachets a day containing the probiotic Vivomixx, for 6 months
Trial: NCT03518268
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention consists of 2 sachets a day of placebo, for 6 months
Trial: NCT01974752
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablets p.o. twice daily taken in combination with dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle.
Trial: NCT00596245
Drug: MT400
RxNorm normalized name: Sumatriptan/naproxen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MT 400, naproxen sodium 550mg
Trial: NCT03554772
Drug: DFN-15 (Celecoxib Oral Solution) 62.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Solution
Trial: NCT03554772
Drug: DFN-15 (Celecoxib Oral Solution) 125 mg
RxNorm normalized name: celecoxib Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Solution
Trial: NCT03554772
Drug: DFN-15 (Celecoxib Oral Solution) 250 mg
RxNorm normalized name: celecoxib Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Solution
Trial: NCT03554772
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Solution
Trial: NCT03859739
Drug: MK-8558
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of MK-8558 administered as a tablet at a dose up to 1600 mg.
Trial: NCT02061397
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eligible patients on sirolimus or everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
Trial: NCT00506155
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg/m\^2 by vein over 15 minutes
Trial: NCT00506155
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 30 mg/m\^2 by vein over 30 minutes
Trial: NCT00203112
Drug: glatiramer acetate with minocycline
RxNorm normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection glatiramer acetate 20mg, with oral minocycline 100mg
Trial: NCT03062618
Drug: PRCL-02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet(s) administered with water
Trial: NCT03062618
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered with water
Trial: NCT01355263
Drug: iron and vitamin a
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00188851
Drug: therapeutic management strategy
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01414205
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants were administered corticosteroids IV prior to the initial dose.
Trial: NCT03523273
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administration will match the study drug.
Trial: NCT00273754
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Children in group one will receive caffeine benzoate 20 mg/kg i.v., which is equal to a 10 mg/kg caffeine base.
Trial: NCT00273754
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children in group two will receive an amount of normal saline equal to Caffeine
Trial: NCT03081676
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03081676
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline)
Trial: NCT00642148
Drug: GW856553
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active tablet
Trial: NCT00642148
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet and inhaler
Trial: NCT01657136
Drug: Beta blocker
RxNorm normalized name: Beta blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparison of different drugs
Trial: NCT00645879
Drug: ornithine alpha ketoglutarate
RxNorm normalized name: ornithine alpha-ketoglutarate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A dose of 400 mg/kg up to 16 g per day was selected. Split into 2 doses taken for 4 weeks. If determined the drug with the best effect, drug will be taken for 30 weeks.
Trial: NCT00885638
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo tablet is given before ingestion of macronutrients
Trial: NCT02262819
Drug: S. aureus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S. aureus, commensal coagulase-negative staphylococcal species, and Gram-negative commensals, such as Roseomonas and Pseudomonas species
Trial: NCT04304794
Drug: Prophylactic administration of antithyroid drugs before iodinated contrast media exposure
RxNorm normalized name: Stellaria media extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13 patients received thiamazole with (6 patients) or without (7 patients) sodium perchlorate, one day prior to iodinated contrast medium (ICM) and for at least 14 days after for thiamazole (20-40 mg/daily) and 10 days after for sodium perchlorate (900 mg/daily).
Trial: NCT03745144
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received placebo matched to cladribine once-daily for 5 consecutive days in treatment period 1 and 2.
Trial: NCT02120365
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given in place of perampanel during the pre-treatment period and lab session days.
Trial: NCT01063842
Drug: tramadol hydrochloride /acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of tramadol hydrochloride/acetaminophen three times daily without titration for 14 days.
Trial: NCT01063842
Drug: tramadol hydrochloride / acetaminophen and placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of tramadol/acetaminophen in the morning, 1 tablet of placebo in the afternoon and evening for 3 days, then 1 tablet of tramadol/acetaminophen in the morning, evening and 1 tablet of placebo in the afternoon for 4 days, then 1 tablet of tramadol/acetaminophen 3 times daily for next 7 days
Trial: NCT03785587
Drug: Sofpironium Bromide Gel, 15%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofpironium Bromide Gel, 15%
Trial: NCT02844283
Drug: Ad-HGF
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02047201
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m2 continuous infusion for 120 h IV (in the vein) every 3 weeks. Number of cycles: 3.
Trial: NCT00882908
Drug: TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC435 will be administered as one or two 75 mg capsules orally, once daily, for 12 or 24 weeks.
Trial: NCT00882908
Drug: PegIFNα-2a (P)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PegIFNα-2a (P) 180 micrograms will be administered as a subcutaneous (under the skin) injection, once weekly for 48 weeks.
Trial: NCT00882908
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules identical in appearance to TMC435 capsule will be administered orally, once daily, for 48 weeks.
Trial: NCT00700102
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed
Trial: NCT02525939
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo tablets
Trial: NCT00196859
Drug: Ibandronate, Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs plus Capecitabine 2000 mg/m2 days 1-14 q d22 x6
Trial: NCT00196859
Drug: Ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs
Trial: NCT03745144
Drug: Microgynon®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received Microgynon® tablet once daily for 21 days in treatment period 1 and 2. Participants received Microgynon® for 21 days, starting on the first day of the menstrual cycle in Run-in period.
Trial: NCT04278937
Drug: Azithromycin Tablets
RxNorm normalized name: Azithromycin Tablets
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: one tablet orally twice daily for three days in 3 courses at 14 weeks, 24 weeks and 32 weeks
Trial: NCT01826266
Drug: PER977, Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01582048
Drug: immunosuppression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conditioning with treosulfan 14 g/m2 day -6 to -4, fludarabine 30 mg/m2/24h day-6 to -2, ATG-Fresenius 20 mg/kg day -4 to -2, rituximab 500 mg/m2 day -1. Unmanipulated PBSC day 0. Postgrafting immunosuppression with mycophenolate mofetil (15 mg/kg TID) and sirolimus (2 mg QD).
Trial: NCT00160199
Drug: PROMETRIUM® 300 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg (3x100mg capsules) by mouth once daily at bedtime for 10 days X 3 cycles
Trial: NCT00160199
Drug: PROMETRIUM® 400 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg (4x100mg capsules) by mouth once daily at bedtime for 10 days X 3 cycles
Trial: NCT02182674
Drug: Placebo Combivent HFA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02182674
Drug: Combivent HFA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02182674
Drug: Placebo Combivent (CFC)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02452853
Drug: FOLFOX4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX4(Oxaliplatin + 5-Fluorouracil/Leucovorin):~4 weeks after HR; Drug: Oxaliplatin + 5- Fluorouracil/Leucovorin Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion. Repeated every 2 weeks
Trial: NCT00302016
Drug: AMN107
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01592019
Drug: Reference, Patch location thigh, batch 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference, Patch location thigh, batch 1
Trial: NCT01592019
Drug: Reference, Patch location abdomen, batch 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference, Patch location abdomen, batch 1
Trial: NCT01853072
Drug: Nepafenac Ophthalmic Suspension, 0.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test intervention
Trial: NCT01853072
Drug: Prednisolone acetate
RxNorm normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks
Trial: NCT04349241
Drug: Standard of care therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oseltamivir 75 mg 12 hourly for 5-10 days and hydroxychloroquine 400mg 12 hourly day -1 followed by 200mg 12 hourly daily on day- 2 to day-5-10
Trial: NCT03490149
Drug: Medication - Treatment as usual
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication only sample - Treatment as usual
Trial: NCT00283816
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsules, two capsules BID
Trial: NCT01571895
Drug: DF2156A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DF2156A is a novel small molecule that inhibits the biological activity of the CXC ligand 8 \[CXCL8; formerly interleukin (IL)-8\] through inhibition of the activation of CXCL8 receptors: CXCR1 and CXCR2. This specific inhibitor stems from a program of drug design of molecules intended to modulate chemokine action.
Trial: NCT03735316
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is a Normal Saline, 5g, IV, Infused once over 15 minutes. The placebo comes in a 250ml glass vial.
Trial: NCT00302458
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered during the first part of the day, and again during the second part of the day.
Trial: NCT01609335
Drug: F-18 FDG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One time intravenous administration of 17 millicurie (mCi) +/- 10%
Trial: NCT00509743
Drug: Intravenous diclofenac sodium (DIC075V)
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: High dose Diclofenac
Trial: NCT00509743
Drug: Intravenous diclofenac sodium (DIC075V)
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low Dose Diclofenac
Trial: NCT03009643
Drug: Inhaled Nitric Oxide
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients are treated with iNO for 3-5 days.The concentration of inhaled Nitric Oxide is around 5-10ppm.
Trial: NCT04701164
Drug: ANX005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for intravenous infusion
Trial: NCT04701164
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for intravenous infusion
Trial: NCT02953665
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (for Liraglutide) 6 mg/ml once daily at a maximum dose of 1.8 mg
Trial: NCT02106247
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT02437604
Drug: Treatment A: Fp MDPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fp MDPI 200 mcg, 1 inhalation
Trial: NCT02437604
Drug: Treatment B: FS MDPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FS MDPI 200/12.5 mcg, 1 inhalation